A beta cell-targeted PD‑1 agonist for type 1 diabetes
A Science Advances paper describes a bispecific ‘ImmTAAI’ molecule that binds a preproinsulin peptide–HLA complex on beta cells and delivers a PD‑1 agonist signal to suppress autoreactive T cells locally in human pancreas slice models. It’s early, but it’s an unusually concrete example of tissue-targeted immunomodulation in type 1 diabetes.